APA (7th ed.) Citation

K, J., J, M., J, A., J, Y., J, R., M, G., . . . A, A. (2019). A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors. Investigational new drugs, 37(2), 307. https://doi.org/10.1007/s10637-018-0662-1

Chicago Style (17th ed.) Citation

K, Jazieh, Molina J, Allred J, Yin J, Reid J, Goetz M, Lim VS, Kaufmann SH, and Adjei A. "A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Epidermal Growth Factor Tyrosine Kinase Inhibitor Erlotinib in Patients with Advanced Solid Tumors." Investigational New Drugs 37, no. 2 (2019): 307. https://doi.org/10.1007/s10637-018-0662-1.

MLA (9th ed.) Citation

K, Jazieh, et al. "A Phase I Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Epidermal Growth Factor Tyrosine Kinase Inhibitor Erlotinib in Patients with Advanced Solid Tumors." Investigational New Drugs, vol. 37, no. 2, 2019, p. 307, https://doi.org/10.1007/s10637-018-0662-1.